The £4 question: what Eden Research's accounts reveal

Eden Research raised £10.8 million at 4 pence per share in February 2026. Three months later, those new shares were worth roughly 2 pence. The fundraise bought the company time and cash, but not price support.

Today, the company published its annual report and set its AGM for 29 September. The accounts cover the fifteen months to 31 March 2026 and paint a familiar picture for small-cap biotech investors: revenue is growing, losses are widening, and the market has decided it wants to be paid back for the patience it's already shown.

The question these accounts force isn't whether the science works. It's whether the business can cross from product approvals to commercial scale before the math turns against it.

The numbers underneath the approvals

Revenue for the 15-month period was £4.9 million, up from £4.3 million in calendar year 2024. That growth is real — and it comes from real product sales. Eden's flagship biofungicide Mevalone has picked up regulatory approvals in France, Italy, California, Kenya, and Chile over the past year. The company has signed new distribution agreements in ornamentals and bee health, and its nematicide Cedroz has a commercial collaborator in Eastman Chemical pursuing global registration.

But the operating side tells a starker story. The operating loss widened to £2.9 million over those fifteen months, up from a £1.9 million net loss in the previous twelve months. The company spent more than it earned by a wide margin.

For context, Eden has two businesses inside one: a commercial operation selling Mevalone today, and a pipeline of products that need field trials, regulatory registrations, and capital before they generate revenue. The £4.9 million in sales is the commercial half. The £2.9 million in losses is the cost of running both halves at once.

The cash math

This is where the accounts become decision-useful.

Eden's cash reserves stood at roughly £1.5 million at the end of the reporting period in March. Then came the fundraise. The £10.8 million raised across a placing, director subscriptions, and a retail offer pushed the cash position to approximately £9 million — as reported in trading updates after the shares were admitted.

The question is what £9 million buys.

Over the trailing twelve months before the fundraise, Eden burned roughly £2.4 million in cash. That translated to a runway of about nine months at that time. The fundraise extended that runway materially. At the same burn rate, £9 million would cover roughly 45 months — almost four years. But that's the old burn rate. Operating losses were widening, not stabilising, as of March 2026. If the company accelerates spending to fund registrations, field trials, and commercial scale-up, the runway shortens. If it pulls back to extend the runway, the commercial timeline slows.

The use-of-proceeds breakdown from February shows where the money is going: roughly £2.8 million for late blight fungicide development, £2.8 million for a wheat fungicide, £1.5 million for commercial-scale programmes, and additional allocations to European insecticide registration and Mevalone development. That is capital-heavy work for a company with £4.9 million in revenue.

The investor takeaway is structural: Eden needs more revenue growth than its current burn rate to make the fundraise sustainable. Not profitable — that's not the bar right now. But revenue has to grow fast enough that the £9 million doesn't disappear into the pipeline before the pipeline itself becomes a revenue engine.

Why the share price fell despite better news

Shares dropped 6.4% on the day the accounts were released in late August. The share price has since moved lower, trading around 2 pence — half the 4 pence investors paid in February.

This isn't a verdict on the business. It's a verdict on dilution and timing.

Eden issued roughly 270 million new shares across the fundraise, more than doubling the share count. Every existing share now represents a smaller slice of the company. The £10.8 million in new cash is real, but it's spread across a much larger capital base. At today's price of around 2 pence, the company's market capitalisation sits below £19 million.

What's also worth understanding is the difference between narrative and factor data. The narrative says Eden is expanding approvals and growing sales. That's correct. The factor data says losses are widening, revenue is still tiny relative to the capital being deployed, and the market has priced in a substantial discount to the fundraise price. Both are true. The narrative tells you the direction the company is heading. The factor data tells you the market doesn't believe the company will get there without spending its way to a decision first.

The sector context — a growing market, not a guarantee

The global biopesticides market is projected to grow from roughly $11.5 billion in 2026 to between $20 billion and $40 billion by the early 2030s, depending on the analyst. That's a 10% to 17% compound annual growth rate — one of the fastest-growing segments in agriculture.

But Eden is not the biopesticide market. It's a single small-cap company inside it, competing against much larger, much more capitalised peers who also have regulatory registrations, distribution networks, and cash balances that make Eden's £4.9 million in revenue look like a research budget. A growing pie doesn't automatically feed every company at the table.

What to watch at the AGM

The AGM on 29 September will give directors the chance to walk shareholders through the full year ahead. The questions that matter aren't rhetorical:

• What is the revenue trajectory for Mevalone over the next twelve months, and how much of it is already contracted versus aspirational?
• How many of the pipeline products require additional capital beyond the £9 million already on the balance sheet?
• Is the burn rate stabilising, or is the company preparing for another fundraise within the next 18 to 24 months?

If the answer to the second question is "most of them," the £9 million won't last four years. If the answer to the first question is "we need distributors to stock our product and disease pressure to cooperate," the revenue timeline depends on factors outside Eden's control.

The investment judgment

Eden Research is the only UK-listed company focused on biopesticides. That's a distinctive position in a growing sector. But distinctive doesn't mean investable — not until the business proves it can convert regulatory approvals into revenue that outpaces its own spending.

The accounts show a company that is doing exactly what early-stage agricultural biotechs do: building product pipelines, securing registrations, and spending capital to reach commercial scale. The £10.8 million fundraise was necessary. The share price decline was the market's way of pricing dilution and execution risk.

For an investor watching from the sidelines, the decision comes down to patience versus process. If you believe the Mevalone and Cedroz pipeline will scale into meaningful revenue over the next three to four years, the current price at around 2 pence represents a steep discount to what new investors paid in February. But that discount exists because the company is still burning more cash than it earns, the share count has more than doubled, and there's no guarantee the pipeline reaches commercial viability before the £9 million runs down.

The factor stack — growing revenue, widening losses, diluted equity, substantial cash — doesn't point to one answer. It points to a binary outcome: the pipeline delivers or it doesn't. In a framework that weights process over conviction, that's not an investment yet. It's a watch list position with a specific catalyst to monitor: whether Mevalone revenue accelerates meaningfully in the next reported results, or whether the burn rate continues to outpace the top line.